Gene therapy works alongside traditional heart failure treatment. Standard medications help manage blood pressure, fluid retention, and cardiac workload. Gene therapy addresses the damaged and dysfunctional cells inside the cardiac muscle itself.
For patients with heart failure driven by a genetic mutation or progressive cellular breakdown, combining both approaches could provide a more comprehensive treatment strategy than either option alone. Heart failure affects more than 6.7 million adults in the United States, and despite significant advances in pharmacological treatment, many patients continue to experience disease progression even when their condition is well-managed.
What Standard Cardiovascular and Heart Failure Treatments Can and Cannot Do
The medications at the center of modern heart failure care have transformed outcomes for patients over the past two decades. Across large randomized trials, these drug classes have demonstrated meaningful reductions in hospitalization, disease progression, and mortality.
For many patients, guideline-directed medical therapy is the difference between a functional life and one defined by the disease. However, there is a ceiling to what these treatments can achieve.
Heart failure is a disease at the cellular level. . The failing myocardium is characterized by:
- impaired calcium handling
- energy deficits at the mitochondrial level
- progressive fibrosis that replaces contractile tissue with scar
Current medications slow these processes; they do not reverse them. Gene therapy is designed to do exactly that.
Four Ways Gene Therapy Targets What Medications Cannot Reach
Cardiac gene therapy delivers corrective genetic material into heart muscle cells using a carrier. That carrier is most commonly an adeno-associated virus (AAV). Once inside the cardiomyocyte nucleus, the therapeutic gene instructs the cell to produce a protein it has lost the ability to make on its own.
The goal is to restore function at the cellular level by addressing the biological processes that standard treatments do not reach . Several specific targets are currently under active investigation:
- Restoring Calcium Cycling With SERCA2a
One of the most studied gene therapy targets in heart failure is SERCA2a. When SERCA2a activity declines, calcium builds up in the cytoplasm after each heart contraction, impairing relaxation and weakening subsequent beats. It’s a compounding problem because the more the pump fails, the harder each contraction becomes.
AAV-mediated delivery of the SERCA2a gene can help restore calcium cycling in pre-clinical models. And when delivered with standard medications that reduce preload and afterload, this approach may address heart failure at multiple levels simultaneously.
- Reducing Fibrosis and Structural Remodeling
Functional muscle is gradually replaced by fibrous scar tissue as heart failure progresses. This structural remodeling stiffens the heart, impairs electrical conduction, and is a major driver of arrhythmia.
However, cardiac fibrosis is also largely irreversible with current pharmacological agents, which can slow its progression but will not undo what has already accumulated. Gene therapy approaches targeting pro-fibrotic signaling pathways could help halt structural remodeling at the molecular level.
Delivered via AAV, anti-fibrotic gene constructs have the potential to preserve viable myocardium at a stage when medications alone are no longer enough to protect it. Speak with your cardiologist to learn more.
- Targeting Mitochondrial Dysfunction
The failing heart is chronically energy-deficient because mitochondrial dysfunction impairs ATP production, which accelerates cardiomyocyte death and limits the heart’s ability to meet even basic metabolic demands.
Gene constructs targeting PGC-1α and related metabolic pathway components could help address this energy deficit directly. These approaches could complement the metabolic effects of SGLT2 inhibitors while targeting a distinct mechanism that those drugs don’t reach.
- Promoting Angiogenesis in Ischemic Heart Failure
In patients with ischemic cardiomyopathy, regions of myocardium that survive an infarction often remain alive but are functionally compromised due to the microvascular supply that was never fully restored.
Angiogenic gene therapy could stimulate new vessel formation in these territories. This approach may improve perfusion to tissue that revascularization procedures and anti-ischemic medications wouldn’t be able to touch. However, the approach is intended to work alongside traditional heart failure treatments, not replace them.
Challenges in Combining Gene Therapy With Existing Care
Pre-existing immunity is often the first and most significant barrier to treating heart failure patients. That’s because a large portion of the general population has been naturally exposed to AAV serotypes, which leave behind neutralizing antibodies that can block vector uptake before the therapeutic gene is able to reach the cardiac tissue.
Patients who test above trial-defined antibody thresholds are typically excluded from clinical programs, even when they are otherwise strong candidates.
Advanced heart failure also creates a more difficult treatment environment at the cellular level. Reduced cardiac output, dense fibrosis, and altered receptor expression on cardiomyocyte surfaces can limit AAV transduction efficiency. So, the patients who have the most to gain from cellular repair may also be the hardest to treat with the platforms currently available.
Drug-Gene Therapy Interactions
The immunosuppressive protocols often required to reduce immune reactions to AAV vectors carry their own cardiovascular and metabolic risks. Coordinating those protocols with the complex pharmacological regimens typical of advanced patients requires careful clinical judgment and close monitoring throughout treatment.
Where the Field Is Headed
The trajectory of cardiac gene therapy research points toward a more layered model of heart failure treatment.
CRISPR and Base Editing in Heart Failure
Many current gene therapy approaches deliver a functional copy of a gene but don’t correct the underlying mutation. Base and prime editing tools change that. Unlike first-generation CRISPR-Cas9, base editors make precise single-nucleotide corrections with a substantially cleaner safety profile.
The clinical significance is meaningful. Rather than compensating for the downstream effects of a genetic mutation, base editing could correct the mutation itself.
Regenerative Medicine and Cellular Repair
Adult cardiomyocytes have an extremely limited capacity to regenerate heart cells after injury. Once the cardiac muscle is lost to infarction or chronic failure, it does not regenerate..
Gene constructs designed to deliver cell cycle regulators such as CCND2 are being researched to stimulate cardiomyocyte proliferation in damaged tissue. If successful, the combination would represent a fundamental shift from managing loss to recovering it through the gene delivery.
The most complete version of that model would involve gene editing to correct a pathogenic variant, gene therapy to restore dysfunctional cellular processes, and medications to protect function throughout, with each layer addressing what the others can’t.
FAQs
Q: Can gene therapy replace my current medications?
Gene therapy could aid existing treatments, however, they are not a substitute. Most active clinical programs are administered alongside standard pharmacotherapy, with each approach targeting a different aspect of heart disease. Patients shouldn’t adjust or discontinue medications without guidance from their cardiac function care team.
Q: How would my care team determine whether I’m a candidate for gene therapy?
Candidate evaluation typically involves disease severity, underlying genetic profile, immune status, and liver function. Patients with single-gene mutations driving their disease are often prioritized in current programs, as are those with advanced disease who have not responded adequately to conventional treatment. Eligibility criteria vary by program and are evolving as clinical evidence accumulates.
Q: Are there active clinical trials combining gene therapy with standard heart failure care?
Several clinical trials are evaluating cardiac gene therapy in patients already receiving guideline-directed medical conventional therapies. Trial eligibility is determined by condition type, disease stage, and serological screening. Patients interested in participating should speak with a cardiologist who specializes in advanced heart failure or genetic cardiomyopathies.
Current Standing and Clinical Outlook
No single health intervention addresses every mechanism driving heart disease. Medications protect the organ, and gene therapy attempts to repair the cells. Used together, however, they could accomplish what neither would be able to achieve alone.
The field is not without its barriers, though. Immune responses, limited re-dosing, reduced vector uptake, and managing these therapies alongside existing regimens are real constraints. But they respond to engineering and clinical innovation, which means significant progress is being made on each front.Visit the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) to follow the latest developments in cardiovascular gene therapy and gene replacement research.
